α1-酸性糖蛋白糖链检测对慢乙肝相关肝硬化的早期诊断及其临床应用

Early diagnosis of chronic hepatitis B-related liver cirrhosis using 1-acid glycoprotein

为探讨α1-酸性糖蛋白(AGP)糖链改变对乙型肝炎相关肝硬化的诊断与临床应用价值,我们研究了239例慢性乙型肝炎及乙型肝炎肝硬化患者,所有患者进行肝功能、血常规、B超、FibroScan等检查,同时测定血清α1-酸性糖蛋白(AGP)特定糖链改变指标LecT-Hepa,分析其对乙肝肝硬化的诊断价值。结果显示LecT-Hepa与FibroScan值呈正相关(r=0.556,P<0.001)。AGP值随慢性乙型肝炎和肝纤维化的进展而升高,在ALT正常组和升高组中分布无明显差别(P=0.160),研究结果显示LecT-Hepa不受肝脏炎症程度的影响,是比较可靠的早期评估慢性乙型肝炎肝硬化的无创性标志物,具有较好的临床应用价值。

To investigate the early diagnostic performance of α1-acid glycoprotein （AGP） for liver cirrhosis in HBV-infected pa tients, two hundred thirty-nine HBV carriers underwent routine serum assays, FibroScan examination, ultrasonic examination, and glyco-alteration（lectT hepa） analysis of serum a-acid glycoprotein （AGP）. The early diagnostic accuracies of AGP in chro nic hepatitis B （CHB）- related liver cirrhosis was analyzed and compared with that of FibroScan test. We found that AGP was correlated positively with FibroScan （ r =0. 556, P d0. 001）and the count distribution of lectT hepa was comparable in both normal and elevated ALT level groups （cutoff value： -7. 469 vs -0. 347 P=0. 160）. Whereas the patients with elevated ALT levels tended to have higher liver stiffness measurement （LSM） than those with normal ALT levels when tested with FibroScan （cutoff value： 28.05KPa vs 8.85KPa, P〈0. 001）. So our results suggested that lectT hepa level might be a reliable noninvasive test for the early evaluation of liver cirrhosis in CHB patients with comparable performance to FibroScan and has proved unaffected by inflammation.